TREATING HYPERURICEMIA OF GOUT: SAFETY AND EFFICACY OF FEBUXOSTAT AND ALLOPURINOL IN OLDER VERSUS YOUNGER SUBJECTS

被引：11

作者：

Becker, Michael A. ^{[1
]}

MacDonald, Patricia A. ^{[2
]}

Hunt, Barbara ^{[2
]}

Gunawardhana, Lhanoo ^{[2
]}

机构：

[1] Univ Chicago, Med Ctr, Pritzker Sch Med, Chicago, IL 60637 USA

[2] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2011年 / 30卷 / 12期

关键词：

Gout; hyperuricemia; elderly; febuxostat; allopurinol; RENAL-FUNCTION; DIURETIC USE; FOLLOW-UP; HEALTH; RISK; CARE; POPULATION; PREVALENCE; DISEASE;

D O I：

10.1080/15257770.2011.603715

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (>= 65 years of age) versus younger (< 65 years of age) patients. In this secondary analysis of data from the CONFIRMS trial, we found that among 374 older subjects, urate-lowering therapy with approved doses of febuxostat or commonly prescribed doses of allopurinol was at least comparable to that in 1894 younger subjects and was well tolerated despite high rates of renal impairment and cardiovascular comorbidities in the older subjects.

引用

页码：1011 / 1017

页数：7

共 17 条

[1]

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial [J].